Literature DB >> 6203521

Kallikrein activation of a high molecular weight atrial peptide.

M G Currie, D M Geller, J Chao, H S Margolius, P Needleman.   

Abstract

Mammalian atrial extracts contain bioactive peptides that exert profound effects upon renal function and isolated smooth muscle preparations. Gel filtration chromatography of rat atrial extract separates the activity into two peaks having apparent molecular weights of 20,000 to 30,000 and less than 10,000. Mild proteolytic treatment (trypsin 1 U/ml) of the high molecular weight fraction enhances the smooth muscle relaxant activity of this fraction and concomitantly reduces the apparent molecular weight of this fraction to less than 10,000. In this report we show that urinary and submaxillary kallikrein enhances the activity of rat atrial extracts in a similar fashion. Pretreatment of the high molecular weight fraction with either kallikrein (1 microgram/ml) enhances the smooth muscle relaxant activity of this fraction. Similar treatment of the low molecular weight fraction had no effect. The enhancement of the bioactivity of the high molecular weight substance(s) by the kallikreins was abolished by aprotinin but was unaffected by soybean trypsin inhibitor. These results suggest that exogenous addition of tissue kallikrein activates a high molecular weight peptide by limited proteolysis. Analysis of the kallikrein-treated high molecular weight peptide fraction by gel filtration indicates that the biological activity comigrates with the low molecular weight peptides present in the original atrial extract.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203521     DOI: 10.1016/0006-291x(84)91276-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Kallikrein-gene expression in the rat gastrointestinal tract.

Authors:  P J Fuller; K Verity; B A Matheson; J A Clements
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

Review 2.  Molecular biology of tissue kallikrein.

Authors:  R J MacDonald; H S Margolius; E G Erdös
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

3.  Identification and characterization of a tissue kallikrein in rat skeletal muscles.

Authors:  N Shimojo; J Chao; L Chao; H S Margolius; R K Mayfield
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

4.  Manipulation of stretch-induced atriopeptin prohormone release and processing in the perfused rat heart.

Authors:  T Ito; Y Toki; N Siegel; J K Gierse; P Needleman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 5.  Molecular aspects of kallikrein and kininogen in the maturing kidney.

Authors:  S S el-Dahr; S Dipp
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

6.  Cardiodilatin-immunoreactive neurons in the hypothalamus of Tupaia.

Authors:  W G Forssmann; V Mutt
Journal:  Anat Embryol (Berl)       Date:  1985

7.  Identification, purification, and localization of tissue kallikrein in rat heart.

Authors:  W Xiong; L M Chen; C Woodley-Miller; J A Simson; J Chao
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

8.  Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininase activity.

Authors:  N B Oza; J H Schwartz; H D Goud; N G Levinsky
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

9.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

10.  Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.

Authors:  J Rehbock; P Buchinger; A Hermann; C Figueroa
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.